362 related articles for article (PubMed ID: 31712648)
1. Cytoreductive treatment strategies for de novo metastatic prostate cancer.
Connor MJ; Shah TT; Horan G; Bevan CL; Winkler M; Ahmed HU
Nat Rev Clin Oncol; 2020 Mar; 17(3):168-182. PubMed ID: 31712648
[TBL] [Abstract][Full Text] [Related]
2. Cytoreductive prostatectomy in metastatic prostate cancer: a systematic review.
Becker JA; Berg KD; Røder MA; Brasso K; Iversen P
Scand J Urol; 2018 Feb; 52(1):1-7. PubMed ID: 28818014
[TBL] [Abstract][Full Text] [Related]
3. Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial.
Connor MJ; Shah TT; Smigielska K; Day E; Sukumar J; Fiorentino F; Sarwar N; Gonzalez M; Falconer A; Klimowska-Nassar N; Evans M; Naismith OF; Thippu Jayaprakash K; Price D; Gayadeen S; Basak D; Horan G; McGrath J; Sheehan D; Kumar M; Ibrahim A; Brock C; Pearson RA; Anyamene N; Heath C; Shergill I; Rai B; Hellawell G; McCracken S; Khoubehi B; Mangar S; Khoo V; Dudderidge T; Staffurth JN; Winkler M; Ahmed HU
BMJ Open; 2021 Feb; 11(2):e042953. PubMed ID: 33632752
[TBL] [Abstract][Full Text] [Related]
4. Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer.
Jalfon MJ; Sakhalkar OV; Lokeshwar SD; Marks VA; Choksi AU; Klaassen Z; Leapman MS; Kim IY
Curr Urol Rep; 2023 Oct; 24(10):455-461. PubMed ID: 37369828
[TBL] [Abstract][Full Text] [Related]
5. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
6. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
7. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer.
Ranasinghe W; Chapin BF; Kim IY; Sooriakumaran P; Lawrentschuk N
BJU Int; 2020 Jun; 125(6):792-800. PubMed ID: 32176456
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.
Heidenreich A; Pfister D; Porres D
J Urol; 2015 Mar; 193(3):832-8. PubMed ID: 25254935
[TBL] [Abstract][Full Text] [Related]
9. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
[TBL] [Abstract][Full Text] [Related]
10. [Cytoreductive, radical prostatectomy in metastatic prostate cancer].
Chaloupka M; Herlemann A; Spek A; Gratzke C; Stief C
Urologe A; 2017 Nov; 56(11):1430-1434. PubMed ID: 28983651
[TBL] [Abstract][Full Text] [Related]
11. Metastatic prostate cancer men's attitudes towards treatment of the local tumour and metastasis evaluative research (IP5-MATTER): protocol for a prospective, multicentre discrete choice experiment study.
Connor MJ; Genie MG; Gonzalez M; Sarwar N; Thippu Jayaprakash K; Horan G; Hosking-Jervis F; Klimowska-Nassar N; Sukumar J; Pokrovska T; Basak D; Robinson A; Beresford M; Rai B; Mangar S; Khoo V; Dudderidge T; Falconer A; Winkler M; Watson V; Ahmed HU
BMJ Open; 2021 Nov; 11(11):e048996. PubMed ID: 34794989
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
[TBL] [Abstract][Full Text] [Related]
13. [Cytoreductive radical prostatectomy for prostate cancer with minimal osseous metastases: results of a first feasibility and case control study].
Heidenreich A; Pfister D; Brehmer B; Porres D
Urologe A; 2015 Jan; 54(1):14-21. PubMed ID: 25519996
[TBL] [Abstract][Full Text] [Related]
14. Despite PSA screening and the control by radical prostatectomy, patients treatment fails and have a PSA recurrence.
Lotan Y
Eur Urol; 2007 Aug; 52(2):453-4. PubMed ID: 17674436
[No Abstract] [Full Text] [Related]
15. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.
Kumar S; Shelley M; Harrison C; Coles B; Wilt TJ; Mason MD
Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD006019. PubMed ID: 17054269
[TBL] [Abstract][Full Text] [Related]
16. The cytoreductive radical prostatectomy in metastatic prostate cancer.
Vladimír Š; Zuzana S; Hana Š
Klin Onkol; 2022; 35(1):55-62. PubMed ID: 35236082
[TBL] [Abstract][Full Text] [Related]
17. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
18. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.
Carrie C; Magné N; Burban-Provost P; Sargos P; Latorzeff I; Lagrange JL; Supiot S; Belkacemi Y; Peiffert D; Allouache N; Dubray BM; Servagi-Vernat S; Suchaud JP; Crehange G; Guerif S; Brihoum M; Barbier N; Graff-Cailleaud P; Ruffion A; Dussart S; Ferlay C; Chabaud S
Lancet Oncol; 2019 Dec; 20(12):1740-1749. PubMed ID: 31629656
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive radical prostatectomy versus no local treatment in patients with metastatic prostate cancer.
González-Browne C; Díaz J; Pinto I; Sandoval C; Vidal Á; Altamirano-Villarroel J
Medwave; 2023 May; 23(4):. PubMed ID: 37233030
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense?
Mathieu R; Korn SM; Bensalah K; Kramer G; Shariat SF
World J Urol; 2017 Apr; 35(4):567-577. PubMed ID: 27502935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
